Company news

TriSalus Life Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

September 25, 2024

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

September 22, 2024

TriSalus Reports Q2 2024 Financial Results and Business Update

August 14, 2024

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

July 31, 2024

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

June 30, 2024

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

June 25, 2024

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

June 2, 2024

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

May 23, 2024

TriSalus Reports Q1 2024 Financial Results and Business Update

May 14, 2024

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

May 6, 2024

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

May 5, 2024

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

April 29, 2024

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

March 31, 2024

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

March 25, 2024

TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

March 20, 2024

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

March 10, 2024

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

March 6, 2024

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

February 28, 2024

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

November 6, 2023

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

November 3, 2023

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 2, 2023

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

October 24, 2023

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

September 5, 2023

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

August 9, 2023

MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

August 1, 2023

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

June 11, 2023

TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases

April 19, 2023

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

February 20, 2023

MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of Stockholders

December 6, 2022

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

November 20, 2022

TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation

November 13, 2022

MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination

March 9, 2022

Memic Announces Adoption of Hominis® Surgical System at Three Leading U.S. Hospitals in Q4 2021

January 5, 2022

Memic Announces Robert L. Ryan and Sandra Morgan to Join Board of Directors Upon Closing of Business Combination with MedTech Acquisition Corporation

September 8, 2021

Peregrine Ventures Portfolio Company Memic Announces $1B Valuation SPAC deal

August 18, 2021

Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination

August 12, 2021

MedTech Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

June 1, 2021

← Newer news releases

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 10 decks. Every deck is listed under its year.